Aimmune Therapeutics is a biopharmaceutical business unit developing and commercializing treatments for potentially life-threatening food allergies. Aimmune’s Palforzia is the first and only FDA and EMA-approved treatment to help reduce the frequency and severity of allergic reactions to peanuts, including anaphylaxis, in children aged 4 through 17.
Choose partners
Image
